source
- Alnylam shares tumble 30% even as biotech sector ralliesAlnylam's stock fell about 30% on July 28, 2026, even though the broader biotech market is experiencing a resurgence. The market rebound follows years of a bearish environment, with increased merg…
- FDA staff raise concerns over Replimune's skin cancer drug dataFDA staff have reiterated concerns that Replimune's investigational skin cancer therapy lacks sufficient data for approval. The agency highlighted the single-arm trial, in which patients previousl…